野生型-话题@MedSci

#野生型#

48篇内容 | 1027人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2082884, encodeId=0eca208288465, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=CSCO 2014：KRAS野生型转移性结直肠癌靶向药物的一线之争, objectType=article, longId=40459, objectId=36774045945, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36774045945, replyNumber=0, likeNumber=38, createdTime=2015-07-24, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36774045945, moduleTitle=CSCO 2014：KRAS野生型转移性结直肠癌靶向药物的一线之争, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36774045945)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082882, encodeId=4fb4208288223, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=Lancet Oncol：帕尼单抗对KRAS野生型转移性结直肠癌非劣于西妥昔单抗（ASPECCT研究）, objectType=article, longId=33909, objectId=cae8339099f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cae8339099f, replyNumber=0, likeNumber=35, createdTime=2014-08-29, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cae8339099f, moduleTitle=Lancet Oncol：帕尼单抗对KRAS野生型转移性结直肠癌非劣于西妥昔单抗（ASPECCT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cae8339099f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082881, encodeId=ae8a2082881a7, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=JAMA：EGFR野生型非小细胞肺癌常规化疗效果更优, objectType=article, longId=33205, objectId=e625332057a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e625332057a, replyNumber=0, likeNumber=23, createdTime=2014-10-13, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e625332057a, moduleTitle=JAMA：EGFR野生型非小细胞肺癌常规化疗效果更优, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e625332057a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082883, encodeId=2681208288380, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果, objectType=article, longId=34270, objectId=a77a342e036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a77a342e036, replyNumber=0, likeNumber=0, createdTime=2015-03-16, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a77a342e036, moduleTitle=CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a77a342e036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082879, encodeId=9db520828e92e, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=WCLC 2013：EGFR野生型NSCLC二线治疗中培美曲塞优于吉非替尼（CTONG 0806研究）, objectType=article, longId=26015, objectId=e591260152f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e591260152f, replyNumber=0, likeNumber=24, createdTime=2013-12-13, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e591260152f, moduleTitle=WCLC 2013：EGFR野生型NSCLC二线治疗中培美曲塞优于吉非替尼（CTONG 0806研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e591260152f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082880, encodeId=92df208288033, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=Lancet Oncol：EGFR野生型NSCLC二线治疗：厄洛替尼不敌标准化疗（TAILOR研究）, objectType=article, longId=26016, objectId=35c626016f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35c626016f7, replyNumber=0, likeNumber=28, createdTime=2014-02-12, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35c626016f7, moduleTitle=Lancet Oncol：EGFR野生型NSCLC二线治疗：厄洛替尼不敌标准化疗（TAILOR研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35c626016f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082877, encodeId=dd4320828e779, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=JNCI：PAK1抑制剂能有效治疗BRAF野生型黑色素瘤患者, objectType=article, longId=16984, objectId=17f01698408, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17f01698408, replyNumber=0, likeNumber=27, createdTime=2013-08-27, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17f01698408, moduleTitle=JNCI：PAK1抑制剂能有效治疗BRAF野生型黑色素瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17f01698408)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082878, encodeId=b67b20828e87d, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=ASCO 2013：培美曲塞二线治疗EGFR野生型NSCLC优于吉非替尼, objectType=article, longId=19770, objectId=349119e7046, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=349119e7046, replyNumber=0, likeNumber=34, createdTime=2013-12-21, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=349119e7046, moduleTitle=ASCO 2013：培美曲塞二线治疗EGFR野生型NSCLC优于吉非替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=349119e7046)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

野生型

2020-05-29

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

CSCO 2014：KRAS野生型转移性结直肠癌靶向药物的一线之争

2015-07-24

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

Lancet Oncol：帕尼单抗对KRAS野生型转移性结直肠癌非劣于西妥昔单抗（ASPECCT研究）

2014-08-29

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

JAMA：EGFR野生型非小细胞肺癌常规化疗效果更优

2014-10-13

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果

2015-03-16

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

WCLC 2013：EGFR野生型NSCLC二线治疗中培美曲塞优于吉非替尼（CTONG 0806研究）

2013-12-13

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

Lancet Oncol：EGFR野生型NSCLC二线治疗：厄洛替尼不敌标准化疗（TAILOR研究）

2014-02-12

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

JNCI：PAK1抑制剂能有效治疗BRAF野生型黑色素瘤患者

2013-08-27

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

ASCO 2013：培美曲塞二线治疗EGFR野生型NSCLC优于吉非替尼

2013-12-21

科室
- - 订阅+
  - 更多科室
工具
服务